Inozyme Pharma, Inc. (INZY)
Inozyme Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $4.00, up 0.25% on the session, giving a market capitalisation of $258.2M. On trailing twelve-month figures it carries a trailing P/E of -2.47, a net margin of 0.0%. Its beta of 2.29 implies it has historically moved more than the broad market.
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.
Inozyme Pharma, Inc. is most often compared with the following Healthcare names: